Skip to main content
. 2021 May 5;12(3):779–795. doi: 10.1002/jcsm.12710

Figure 6.

Figure 6

DCSD ameliorated muscle wasting and fat degradation in C26 tumour‐bearing mice. C26 tumour‐bearing mice were administrated DCSD (20 mg/kg) by intraperitoneal injection every day for 16 days, and healthy BALB/c mice and C26 model group mice received equal volume solvent. The GA muscle tissues and eWAT were dissected, weighed, and then fixed in 4% PFA at the end of the experiment. (A, B) GA weight of each group mice with or without treatment of DCSD. (C, D) H&E‐stained sections of mice GA and quantify the myofibres cross‐sectional area of GA tissues with or without treatment of DCSD. Scale bar, 50 μm. (E, F) eWAT weight of each group mice with or without treatment of DCSD. (G, H) H&E‐stained sections of mice eWAT and quantify the adipocytes cross‐sectional area of eWAT with or without treatment of DCSD. Scale bar, 50 μm. (I, J) Content of glycerol and TG in serum with or without treatment of DCSD. Values are expressed as mean ± SEM (n = 8). *vs. healthy control group mice; #vs. C26 model group mice. One‐way ANOVA test was performed followed by Bonferroni's post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.05, ##P < 0.01, ###P < 0.001.